IL132520A0 - A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor - Google Patents

A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor

Info

Publication number
IL132520A0
IL132520A0 IL13252098A IL13252098A IL132520A0 IL 132520 A0 IL132520 A0 IL 132520A0 IL 13252098 A IL13252098 A IL 13252098A IL 13252098 A IL13252098 A IL 13252098A IL 132520 A0 IL132520 A0 IL 132520A0
Authority
IL
Israel
Prior art keywords
inhibitor
pharmaceutical composition
protein kinase
skin disorders
treating skin
Prior art date
Application number
IL13252098A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL132520A0 publication Critical patent/IL132520A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
IL13252098A 1997-04-30 1998-04-21 A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor IL132520A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4443197P 1997-04-30 1997-04-30
PCT/US1998/007808 WO1998048795A1 (en) 1997-04-30 1998-04-21 Therapeutic treatment for skin disorders

Publications (1)

Publication Number Publication Date
IL132520A0 true IL132520A0 (en) 2001-03-19

Family

ID=21932346

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13252098A IL132520A0 (en) 1997-04-30 1998-04-21 A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor

Country Status (16)

Country Link
US (1) US6093740A (xx)
EP (1) EP0903145A3 (xx)
JP (1) JP2002501501A (xx)
KR (1) KR20010020381A (xx)
CN (1) CN1259866A (xx)
AU (1) AU7131898A (xx)
BR (1) BR9809343A (xx)
CA (1) CA2289257A1 (xx)
EA (1) EA199900987A1 (xx)
HU (1) HUP0002836A2 (xx)
ID (1) ID23528A (xx)
IL (1) IL132520A0 (xx)
NO (1) NO995231L (xx)
PL (1) PL336760A1 (xx)
TR (1) TR199902682T2 (xx)
WO (1) WO1998048795A1 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE300957T1 (de) * 1998-12-22 2005-08-15 Genentech Inc Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
CA2395136A1 (en) * 1999-12-22 2001-06-28 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20070032479A1 (en) * 2003-12-03 2007-02-08 Leventer Steven M Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
US8367609B2 (en) * 2006-01-18 2013-02-05 The General Hospital Corporation Methods of reducing skin damage and edema
US7455447B2 (en) * 2006-05-19 2008-11-25 Mediatek Inc. Method and apparatus for a portable device
CN101380317B (zh) * 2007-09-07 2010-12-08 英属开曼群岛商安盛开发药物股份有限公司 减缓搔痒症的药学组合物
ES2633343T3 (es) * 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal
WO2018118874A1 (en) * 2016-12-19 2018-06-28 Chromaderm, Inc. Methods of treating hyperpigmentation disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
AU687909B2 (en) * 1993-12-07 1998-03-05 Eli Lilly And Company Protein kinase C inhibitors
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
HUT69164A (en) * 1993-12-07 1995-08-28 Lilly Co Eli Improved process for producing bis-indolyl-maleimide derivatives
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
SI0776895T1 (en) * 1995-11-20 1999-04-30 Eli Lilly And Company Protein kinase C inhibitor
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
BR9710706A (pt) * 1996-05-01 1999-08-17 Lilly Co Eli Tratamento terap-utico para doen-as relacionadas a vegf

Also Published As

Publication number Publication date
EP0903145A3 (en) 2001-02-07
WO1998048795A1 (en) 1998-11-05
PL336760A1 (en) 2000-07-17
US6093740A (en) 2000-07-25
BR9809343A (pt) 2000-07-04
CA2289257A1 (en) 1998-11-05
HUP0002836A2 (hu) 2001-02-28
EA199900987A1 (ru) 2000-08-28
TR199902682T2 (xx) 2000-05-22
AU7131898A (en) 1998-11-24
CN1259866A (zh) 2000-07-12
NO995231L (no) 1999-12-27
ID23528A (id) 2000-04-27
NO995231D0 (no) 1999-10-26
KR20010020381A (ko) 2001-03-15
EP0903145A2 (en) 1999-03-24
JP2002501501A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
EG23871A (en) Protein kinase c inhibitor
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
HK1025904A1 (en) Pharmaceutical composition for combination of piperidinoalkanol-decongestant
CY2561B1 (en) Protein kinase C inhibitors
IL117237A0 (en) Pharmaceutical composition for piperidinoalkanol compounds
IL132520A0 (en) A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor
IL118590A (en) Pharmaceutical composition for minimizing bone loss
ZA964373B (en) A pharmaceutical composition for treating lukemia
HUP9903684A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating depression
EP1012150A4 (en) HETEROARYLCARBOXAMIDE COMPOUNDS THAT ARE EFFECTIVE OF DISEASES CAUSED BY PROTEIN-TYROSIN-KINASE
HUP0003679A3 (en) Use of pkc inhibitors for the preparation of pharmaceutical compositions treating cardiovascular diseases
HU9800396D0 (en) Pharmaceutical composition for treating dementia
IL128351A0 (en) Pharmaceutical composition for treating viral diseases
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
ZA949611B (en) Protein kinase C inhibitors
EP1007041A4 (en) COMPOSITION FOR TREATING PAIN
KR100248098B1 (en) Pharmaceutical composition for the treatment of dementia
AU2003200309A1 (en) Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases
HUP9903978A3 (en) Use of inhibitors of protein glycation for the treatment of type ii diabetes
HUP0003236A3 (en) Medicinal compositions for treating immunodeficiency diseases
IL116680A0 (en) Pharmaceutical composition for the treatment of depression
AUPO882597A0 (en) Pharmaceutical composition for the treatment of skin disorders
IL121488A0 (en) A pharmaceutical composition for the treatment of multiple sclerosis
HUP9702369A3 (en) Pharmaceutical composition of natural active components for treating kinetose
SI0657458T1 (en) Protein kinase C inhibitors